Enhertu Recovery Time
There is no standardized "recovery time" after Enhertu (trastuzumab deruxtecan) infusions—patients remain on continuous 3-week cycles until disease progression or unacceptable toxicity, with treatment duration varying widely from less than 1 month to over 30 months. 1
Treatment Schedule and Duration
Enhertu is administered as an intravenous infusion every 3 weeks (one cycle = 21 days). The concept of "recovery" differs from traditional chemotherapy because:
- Continuous therapy model: Patients continue treatment indefinitely until progression or toxicity, not for a fixed number of cycles 1
- Median treatment duration: In clinical trials, patients received Enhertu for a median of 14 months (range: 0.7 to 30 months) in the DESTINY-Breast03 study 1
- Extended exposure common: 67% of patients were exposed for >6 months and 38% for >12 months across pooled studies 1
Managing Toxicities During Treatment
Dose Interruptions and Modifications
Treatment interruptions occurred in 44% of patients, most commonly for:
- Neutropenia, leukopenia, anemia, thrombocytopenia (hematologic toxicities)
- Nausea and fatigue
- Interstitial lung disease/pneumonitis 1
Dose reductions occurred in 21% of patients, primarily for:
- Nausea
- Neutropenia
- Fatigue 1
Critical Safety Monitoring
Interstitial lung disease (ILD)/pneumonitis is the most serious toxicity requiring vigilance:
- Occurred in 11% of patients overall (8% led to permanent discontinuation)
- Higher risk in patients with moderate renal impairment—monitor these patients more frequently 1
- Three fatal cases (Grade 5) reported in recent trials 1, 2
Post-Treatment Considerations
After Discontinuation
Permanent discontinuation occurred in 14% of patients 1. When considering subsequent therapy:
- Post-Enhertu treatment options show limited efficacy: Median time to treatment failure after Enhertu was only 3.5 months (95% CI 2.1-10.03) 3
- Regimens containing trastuzumab may be more effective than HER2 tyrosine kinase inhibitors alone 3
- Patients who developed Enhertu-related ILD had worse outcomes with subsequent therapy (median TTF 2.33 months vs 3.83 months) 3
Contraception Requirements
Due to embryo-fetal toxicity risks:
- Females: Use effective contraception during treatment and for 7 months after the last dose 1
- Males: Use effective contraception during treatment and for 4 months after the last dose 1
Clinical Context
The question of "recovery time" may reflect concerns about:
- Infusion day logistics: Each infusion takes several hours; patients typically return home the same day
- Cycle-to-cycle management: The 3-week interval allows for hematologic recovery and toxicity assessment before the next dose
- Long-term treatment planning: Unlike traditional chemotherapy with defined endpoints (4-6 months), Enhertu continues until progression, making "recovery" an ongoing management issue rather than a discrete endpoint
Key pitfall: Do not assume Enhertu follows traditional chemotherapy patterns with a fixed number of cycles followed by a treatment-free recovery period. This is maintenance therapy requiring continuous monitoring and proactive toxicity management, particularly for ILD/pneumonitis which can occur at any time during treatment.